1	Preclinical Evaluation of a Novel Single-Shot Pulsed Field Ablation System
2	for Pulmonary Vein and Atrial Ablation
3	
4	
5	Short titles DEA Using a New I Single Shot Ablation Sustan
0 7	Short live: PFA Using a Novel Single-Shot Adlation System
8	
9	
10	Arash Aryana, MD, PhD ¹ , Sang Yong Ji, MD ² , Cary Hata, BS ³ , Alan de la Rama, BS ³ , Ken
11	Nguyen, BS ³ , Dorin Panescu, PhD ³
12	
13 14	
14	¹ Mercy General Hospital and Dignity Health Heart and Vascular Institute Sacramento CA
16	² COR Healthcare, Torrance, CA
17	³ CRC EP, Inc, Tustin, CA
18	
19	
20	
21 22	Word Count: 4 549
23	Word Count. 4,547
24	
25	
26	Conflicts of Interests: Drs. Aryana and Ji have received consulting fees from CRC EP, Inc. Dr.
27	Panescu, Mr. Hata, Mr. de la Rama and Mr. Nguyen are employees of CRC EP, Inc.
28 29	
29 30	
31	
32	Funding: This study was sponsored by CRC EP, Inc.
33	
34	
35 36	
37	Address for Correspondence:
38	Arash Arvana, MD, PhD
39	Director. Greater Sacramento Cardiovascular Services
40	Dignity Health Heart and Vascular Institute
41	Director. Cardiac Electrophysiology Laboratory
42	Mercy General Hospital
43	3941 J Street, Suite #350
44	Sacramento, CA 95819
45	E-mail: a aryana@outlook.com
46	

Abstract

48	BACKGROUND: Pulsed field ablation (PFA) is a non-thermal ablative strategy that achieves
49	cell death via electroporation. We investigated the preclinical safety and efficacy of PFA using
50	two novel 8-French, 16-electrode spiral PFA/mapping catheters (CRC EP, Inc).
51	METHODS: Bipolar PFA (>1.8 kV) was performed using 30 s, single-shot, QRS-gated
52	applications. Ninety-four atrial structures were ablated in 23 swine, 1 canine, and 1 ovine,
53	including right and left atria and atrial appendages, pulmonary veins, and superior and inferior
54	(IVC) vena cavae. Additionally, we examined the impact of PFA on the phrenic nerve in 14
55	swine and on a deviated esophagus during ablation from inside the IVC in 5 swine.
56	RESULTS : All applications were single-shot without repositioning the catheter. Minimal
57	microbubbling was observed without significant skeletal muscle twitching/activation (mean
58	acceleration: 0.05 m/s^2). There was marked reduction in the post- versus pre-PFA atrial
59	electrogram amplitude (0.17±0.21 mV vs. 1.18±1.08 mV; P<0.0001). Durable conduction block
60	was demonstrated up to 3 months in all targeted tissues. Lesions were contiguous and transmural,
61	measuring 25±9 mm x 21±7 mm without any thermal effects. Magnetic resonance, gross, and
62	histologic examinations of the brain, rete mirabile and kidneys revealed no thromboembolism.
63	No acute/long-term phrenic nerve dysfunction was encountered. Though within 2 hours of
64	ablation, histologic examinations of the esophagus revealed acute PFA-related changes in the
65	muscular layer, these completely resolved by 21 ± 5 days.
66	CONCLUSION: A novel, single-shot, spiral PFA system is capable of safely creating large,
67	durable atrial lesions without significant adverse effects on the phrenic nerve or the esophagus.
68	

- **KEYWORDS:** catheter ablation; electroporation; esophagus; left atrium; phrenic nerve;
- 70 pulmonary vein isolation; pulsed field ablation

71 Introduction

72 Pulsed field ablation (PFA) utilizes intermittent, high-intensity electric field for short 73 durations (micro- or nanoseconds) to achieve cell death through irreversible electroporation.^{1,2,3} Most unique to PFA is its tissue selectivity.⁴ That is, different tissues have specific characteristic 74 threshold field strengths that induce necrosis.⁵ Preclinical and clinical studies have found that 75 76 cardiac myocytes in general exhibit a lower threshold for irreversible electroporation as compared to phrenic nerve (PN) or esophageal tissue.^{6,7,8,9} In this preclinical study, we 77 78 demonstrate the feasibility and safety of two novel, 8-French, 16-electrode, single-shot, bipolar, 79 spiral PFA/mapping catheters (CRC EP, Inc, Tustin, CA). 80 **Methods** 81 All preclinical experiments were approved by the Institutional Animal Care and Use 82 83 Committee at the Sutter Institute for Medical Research (Sacramento, CA). A total of 23 84 Yorkshire or Yucatan swine (52–92 kg), 1 canine (27 kg), and 1 ovine (73 kg) were included in

this study. Given that these were initial experiments, randomization and sample size calculationwere not performed.

87

88 a. CRC EP ablation catheter and system.

89 PFA was performed using one of the two bipolar, non-irrigated, spiral PFA catheters 90 (ElePulse, CRC EP, Inc) and a custom programmable PFA generator (CRC EP, Inc). The 91 catheters consist of an 8-French, 16-electrode, bidirectional, 25-mm or 30-mm design with 92 radiopaque tips, intended for single-shot ablation, with the larger of the two catheters (30-mm) 93 containing 4 distal mapping electrodes. **Figure 1**, illustrates the design of the two PFA/mapping

94	catheters and the ablation system. Briefly, the catheters are inserted through a commercially-
95	available 8.5-French, long introducer. The system delivers biphasic, microsecond-wide pulses
96	with amplitudes in excess of 1.8 kV. The generator allows for PFA using individually-selected
97	electrodes or simultaneously using all 16 electrodes. With the exception of the first 4 consecutive
98	animals, PFA pulses were synchronized with the cardiac cycle through QRS gating using a
99	cardiac trigger monitor (Ivy Biomedical Mode 7600, Ivy Biomedical Systems, Inc, Branford,
100	CT), to avoid energy delivery during the vulnerable period.

- 101
- 102

b. Preclinical protocols.

103 After an overnight fast, all swine were anesthetized, intubated, and ventilated 104 mechanically with 1.0 FiO₂ air. The animals were pretreated with ceftiofur (360 mg) on the day 105 before and with gentamicin (160 mg) on the day of procedure. General anesthesia was induced 106 by tiletamine (350 mg) and maintained using inhalational isoflurane (2.5%). A decapolar 107 diagnostic electrophysiology catheter (Response, Abbott, Chicago, IL) was inserted into the 108 coronary sinus for left atrial (LA) recording and pacing via the right internal jugular vein. 109 Following percutaneous femoral venous access and systemic anticoagulation, a single transseptal 110 puncture was performed for LA access. An 8.5-French deflectable introducer (Agilis, Abbott) 111 was used for mapping and ablation under intracardiac echocardiographic (ViewMate, Abbott) 112 guidance. Single-shot, QRS-gated, bipolar PFA (>1.8 kV) was performed using 30 sec 113 applications. The targeted structures included the right atrium (RA), RA appendage (RAA), right 114 superior PV, right inferior PV, left PV (also known as left inferior common PV), LA appendage, 115 LA posterior wall, and superior (SVC) and inferior (IVC) vena cavae. Pre- and post-PFA intracardiac electrograms, pacing thresholds, and electrical isolation/conduction block were 116

assessed. In addition, detailed pre- and post-PFA voltage maps were created using a high-density
mapping catheter (Advisor HD Grid, Abbott) in all swine (bipolar voltage cutoff <0.1 mV).
Upon completion of the study, the animals were euthanized. In addition to pre- versus post-PFA
electrogram amplitudes, pacing thresholds, conduction block, and 3D voltage mapping (EnSite,
Abbott), PFA lesions were also analyzed by necropsy and histology.

- 122
- 123

c. Skeletal muscle activation studies.

124 The intensity of skeletal muscle activation was quantified by measuring the absolute 125 acceleration of muscular contractions. Briefly, a smartphone (Galaxy S6, Samsung Electronics, 126 Suwon-si, South Korea) was secured to the animal's thorax. The Phyphox smartphone 127 application (Physical Phone Experiments, RWTH Aachen University, Aachen, Germany) was 128 utilized which uses an integrated acceleration sensor. Acceleration was measured on the x, y, and 129 z coordinates and computed in absolute values. This allowed for assessment of acceleration 130 resulting from contractions triggered by PN stimulation as well as contractions triggered during 131 PFA energy delivery. Meanwhile, we specifically also tested the PFA system in the ovine (n=1), 132 as it is widely-believed that this animal model may be more sensitive to skeletal muscle 133 activation. Lastly, in one animal an intravenous paralytic agent (succinylcholine 1 mg/kg) was 134 administered to confirm PN-mediated loss of skeletal muscle contraction during PFA. In other 135 words, acceleration measurements were recorded without and with administration of paralytics 136 with the catheter positioned at the same location and using the same PFA energy parameters. 137

138 d. PN safety studies.

139 We specifically assessed the safety of PFA with regard to the PN in 14 swine (66 ± 13 kg). 140 PFA was intentionally performed at anatomical locations exhibiting low-output PN pacing 141 capture using the PFA catheter, such as the SVC, the RAA and the LAA. PN function was 142 evaluated through pacing capture, pre-versus post-PFA, acutely and during follow-up (up to 3 143 months post-ablation). In addition, the PNs were closely examined in all animals at necropsy and 144 histology.

145

146

e. Esophageal safety studies.

147 To assess the safety of PFA on the esophagus, PFA was performed from within the IVC 148 toward a deviated esophagus deflected toward the ablation catheter in 5 swine, as described in a previously-reported protocol.⁹ Briefly, following systemic anticoagulation, the PFA catheter was 149 150 inserted through an 8.5-French deflectable introducer (Agilis, Abbott). Next, the esophagus was 151 intubated using an esophageal balloon retractor device (DV8, Manual Surgical Sciences Inc, Salt 152 Lake City, UT) under fluoroscopy. The distal esophageal lumen was anatomically delineated by 153 administering iodinated contrast medium through an open port in the esophageal retractor device. 154 The esophageal retractor was then inflated with a mixture of saline and contrast for fluoroscopic 155 visualization and rotated to physically deviate the esophagus toward the PFA catheter placed 156 inside the IVC. The deflectable sheath was used to ensure forceful contact between the ablation 157 catheter and the esophagus. Orthogonal fluoroscopic views were used to confirm the immediate 158 proximity of the deviated esophagus to the ablative portion of the catheter within the IVC 159 (Supplemental Figure 1). Whenever possible, the PFA catheter was also used to mechanically 160 displace luminal contrast within the esophagus to further confirm its proximity to this structure. PFA was then delivered using the spiral catheter at areas intentionally contacting the deviated 161

162	esophagus. Post-mortem, the esophagus was removed in its entirety, carefully inspected and
163	photographed. The lesions created within the IVC and the esophagus were analyzed by gross and
164	histologic examination. Esophageal sections were evaluated for alterations within the normal
165	architecture as well as inflammation, necrosis, or fibrosis.
166	
167	f. Assessment for thromboembolization.
168	1. Systemic embolization.
169	In all the animals, the brain, the kidneys, and the liver were carefully removed at necropsy
170	and thoroughly examined for signs and evidence of thromboembolism. If any gross
171	abnormalities were detected, further histologic examinations were performed.
172	2. The rete mirabile model.
173	The swine rete mirabile model was further used to investigate the potential embolic
174	effects of PFA using the current system. ¹⁰ As such, the rete mirabile was meticulously analyzed
175	grossly and microscopically in 6 swine that received multiple PFA applications to the RAA, right
176	superior PV, right inferior PV, left PV, LAA, and the LA posterior wall.
177	3. Magnetic resonance imaging (MRI).
178	In 3 swine, brain T2-weighted MRI scanning was also performed at baseline and at 1
179	week post-PFA for comparison to assess for cerebral emboli. MRI scanning was performed using
180	a Philips MR 5300 Scanner (Philips, Eindhoven, Netherlands) and the images carefully analyzed
181	for abnormalities by a radiologist.
182	
183	g. Follow-up studies and histologic analysis.

184 Two swine, 1 canine, and 1 ovine were euthanized within 4 h of PFA to investigate the 185 acute effects of tissue ablation. Sixteen animals were survived for 3-4 weeks and 3 swine for 3 186 months. In all animals, high-density 3D voltage mapping (Advisor HD Grid, Abbott) was 187 performed post-PFA and again repeated during follow-up on the day of sacrifice (range: 3 weeks 188 to 3 months) to reassess lesion durability. Ablation efficacy was further validated by the analysis 189 of intracardiac electrograms, pacing thresholds, and electrical isolation/conduction block. At 190 necropsy, all cardiac chambers were carefully examined and all lesions were identified and 191 photographed. Detailed analysis of each treatment site was performed and measurements were 192 taken to determine the dimensions of the ablation lesions. In addition, all tissues were fixed in 193 formalin, processed, and stained with hematoxylin and eosin and elastin Masson trichrome. 194

195 Statistical methods

The data are represented as mean ± standard deviation. Continuous variables were
analyzed using a two-sample *t* test. All P-values were two-sided and a P-value of <0.05 was
considered statistically significant. The analyses were conducted using Stata 14 (StataCorp LP,
College Station, TX).

200

201 **Results**

202 During this study, 94 structures were ablated in 25 healthy animals including 23 swine, 1

203 canine, and 1 ovine. The targeted structures included: RA (5), LA posterior wall (2), RAA (6),

204 LAA (14), right superior PV (22), right inferior PV (20), left PV (16), SVC (4) and IVC (5).

205 Each structure was ablated using 1.1±0.2 PFA applications resulting in successful

ablation/isolation (Figure 2). Real-time locations of the spiral PFA catheter during ablation were

207	recorded within the 3D map (Figure 3). Given the advent of QRS gating, no ventricular
208	arrhythmias were inadvertently triggered during PFA. Meanwhile, PFA resulted in marked
209	reduction in the post- versus pre-PFA electrogram amplitudes (0.17±0.21 mV vs. 1.18±1.08 mV;
210	P<0.0001) as well as a significant increase in the post- versus pre-PFA pacing threshold at the
211	ablated sites (>15 mA versus 0.6±0.7 mA, P<0.001) (Table 1). Minimal microbubbling and no
212	discernable skeletal muscle twitching was observed during PFA. Though administration of an
213	intravenous paralytic agent (succinylcholine 1 mg/kg) temporarily abolished all forms of skeletal
214	muscle twitch/activation; in the absence of a paralytic agent, PFA at sites adjacent to the
215	right/left PN (e.g., lateral RA or LAA) commonly resulted in visible PN capture and hemi-
216	diaphragmatic stimulation. Yet, there was no incidence of diminished PN function during or
217	post-PFA as confirmed by low-output PN pacing capture using the PFA catheter. When PN
218	pacing capture was present (e.g., when targeting the right superior PV), acceleration levels were
219	measured in the range of 5–9 m/s ² . When ablating structures remote from the right/left PNs ($e.g.$,
220	the left PV), the absolute mean acceleration was only 0.05 m/s^2 which was indiscernible from the
221	background noise level (Supplemental Figure 2).

222 Complete and durable conduction block was demonstrated acutely and up to 3 months 223 post-PFA (Figure 4). All lesions were large and durable at follow-up (range: 3 weeks to 3 224 months). Histologically, the PFA lesions were contiguous and transmural (Figure 5), measuring 225 25±9 mm x 21±7 mm and 7.6±1.6 mm deep. No evidence of collateral injury or abnormalities 226 involving the PN (Figure 5) could be detected in any of the animals, including the 8 swine in 227 which the PNs were intentionally targeted – neither acutely, nor during follow-up at 3-4 weeks 228 post-PFA. Additionally, there were no observed cases of vascular injury. Likewise, gross and 229 microscopic examinations of the brain, the rete mirabile, the kidneys, the liver, the lungs, and the

bronchi revealed no evidence of embolization or adjacent structure/tissue injury in any of the
animals (Figure 6). Moreover, post- versus pre-PFA T2-weighted MRI scanning (n=3 swine)
did not show any evidence of embolic events.

233 In 5 swine (62 ± 12 kg), 14 PFA applications were delivered within the IVC toward an 234 opposing esophagus, intentionally deviated toward/adjacent to this structure. All 14 animals 235 completed the follow-up period without clinical sequelae. Their body weights increased by 236 15±4% during follow-up. All IVC treatments were transmural, measuring 15.6±5.5 mm x 237 5.9±1.4 mm. Histopathologic examinations revealed acute PFA-related changes in the 238 esophageal muscular layer which appeared within 2 h of PFA (Figure 7). However, these 239 changes completely resolved by 21 ± 5 days of follow-up. No other acute or chronic 240 lesions/abnormalities were detected in the esophageal mucosa or submucosa in any of the 5 241 animals at 3 weeks of follow-up.

242

243 **Discussion**

244 PFA is primarily a non-thermal ablative strategy that relies on pulsed applications of 245 high-intensity electric fields for short durations which result in cellular and tissue electroporation.¹ This phenomenon represents a process whereby the applied electric field results 246 247 in the formation of pores within the cell membrane. Depending on the parameters of the applied 248 electric fields, pore formation can lead to permeabilization which may be either reversible or 249 irreversible. In reversible electroporation, cells remain viable and this process underlies the basis 250 of electrochemotherapy and gene electrotransfer. Conversely, irreversible electroporation renders 251 cells and tissues nonviable as a consequence of the programmed cell death cascade. Irreversible

electroporation has recently been revisited in a number of preclinical and clinical studies with
favorable outcomes for the treatment and ablation of atrial and ventricular tissues.^{4,5,7,8}
Furthermore, irreversible electroporation can create lesions without tissue heating and is also
believed to be tissue/cell selective enabling preservation of the adjacent or surrounding
structures.

257 This initial *in vivo* study illustrates the safety and efficacy of a novel, bipolar, single-shot 258 family of PFA catheters for the treatment and ablation of atrial tissue. The lesion durability and 259 the histopathologic findings described in this report are highly consistent with prior reports using 260 different biphasic waveforms delivered with other multipolar PFA catheters. Accordingly, the 261 PFA catheters investigated in this study proved capable of creating large, transmural atrial 262 lesions. The PFA applications were generally single-shot and did not require catheter 263 repositioning resulting in acute marked reduction in post-versus pre-PFA electrogram 264 amplitudes. Moreover, all PFA lesions were found to be completely durable up to 3 months of 265 follow-up and despite minimal microbubbling observed during ablation, no discernable embolic 266 events were encountered by MRI or careful histologic analysis of the brain, the rete mirabile, and 267 the systemic organs.

Also, consistent with prior reports, PFA using the studied catheter system did not produce any collateral damage to the bronchi or PN, nor any long-term injuries to a manually-deviated, esophagus when performing ablations within the adjacent IVC. Though by design, the findings from such a simulation bear obvious limitations, this model does indeed offer certain clinical merits. As previously described,⁹ it involves manual deviation of the esophagus toward/against the PFA catheter placed transvenously within the IVC, to approximate the anatomical proximities required to simulate esophageal injury during LA ablation. The inherent advantage

275 of this model is that it allows for delivery of the ablative energy over a large area of the 276 esophageal tissue, within the blood pool as in the case of LA ablation, while affording placement of multiple ablation lesions for analysis.⁹ In addition, it represents ablation within an intra-277 278 vascular milieu similar to conventional clinical workflows allowing for assessment of PFA 279 lesions delivered directly on a thin-walled structure (*i.e.*, the IVC) similar to the posterior LA wall. Also, given that the posterior LA wall shares its embryologic origins with PV tissues¹¹ and 280 that the electrical conductivity of the IVC is similar to that of the posterior wall of the LA.¹² 281 282 these characteristics render this model both relevant and clinically suitable. Meanwhile, similar to previously published reports,¹³ the findings from this study showed evidence of acute, but 283 284 transient PFA-related changes within the muscularis layer of the deviated esophagus when 285 delivering PFA applications in the adjacent IVC, which completely resolved at 3 weeks of 286 follow-up without any detectable long-term sequelae. Although these findings appear highly 287 promising, future studies and clinical investigations are clearly warranted to further validate the 288 safety and efficacy outcomes reported in this preclinical study.

289

290 Limitations

The authors recognize several important limitations in this study. First, as with all preclinical studies, there are anatomic and physiologic differences between humans and quadrupeds that may limit translation of the study results. Second, the tissue specificity of PFA can be altered with even small changes in the delivery parameters, including waveform composition and catheter electrode design and configuration. Therefore, the results described herein cannot be assumed to be applicable to other PFA systems. Third, the esophageal deviation model proposed and used in this study represents merely an approximation of clinical conditions

and scenarios. Moreover, the lack of endoscopic examination of the studied animals could have
limited our assessment of reversible esophageal injury at earlier time points. Finally, the
preclinical findings reported in this study require validation through clinical studies prior to
adoption for clinical use.

302

303 Conclusions

In this initial study, we demonstrate that endocardial ablation can be performed safely and effectively using a novel family of bipolar, single-shot, spiral PFA/mapping catheters. Furthermore, this PFA system allows for creation of wide, transmural lesions within the atria and durable PV isolation without significant skeletal muscle twitch/activation, thromboembolism, collateral injury to the PN or bronchi or long-term abnormalities in the adjacent esophagus when

309 manually deviated to render contiguous with the site of the energy source.

310

311 Acknowledgments

The authors wish to sincerely thank Taylor Spangler, DVM, DACVP for performing gross and histologic analyses on all the examined tissues. The authors also wish to thank Keith Pound, MS for his assistance with 3D mapping during this study.

315

316 Sources of Funding

317 This study was supported by CRC EP, Inc.

318

319 **Conflicts of Interests**

- 320 Drs. Aryana and Ji have received consulting fees from CRC EP, Inc. Dr. Panescu, Mr.
- Hata, Mr. de la Rama and Mr. Nguyen are employees of CRC EP, Inc.

References

323	1.	Maor E, Sugrue A, Witt C, et al. Pulsed electric fields for cardiac ablation and beyond: A
324		state-of-the-art review. Heart Rhythm 2019;16:1112-1120.
325	2.	Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of
326		electrochemotherapy: A systematic review and meta-analysis. Eur J Surg Oncol
327		2013;39:4–16.
328	3.	Heller R, Heller LC. Gene electrotransfer clinical trials. Adv Genet 2015;89:235-262.
329	4.	Reddy VY, Koruth J, Jais P, et al. Ablation of atrial fibrillation with pulsed electric
330		fields: An ultra-rapid, tissue-selective modality for cardiac ablation. JACC Clin
331		Electrophysiol 2018;4:987–995.
332	5.	DeSimone CV, Kapa S, Asirvatham SJ. Electroporation: Past and future of catheter
333		ablation. Circ Arrhythm Electrophysiol 2014;7:573–575.
334	6.	Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation on nerves.
335		PLoS One 2011;6:e18331.
336	7.	Koruth JS, Kuroki K, Kawamura I, et al. Focal pulsed field ablation for pulmonary vein
337		isolation and linear atrial lesions: A preclinical assessment of safety and durability. Circ
338		Arrhythm Electrophysiol 2020;13:e008716.
339	8.	Stewart MT, Haines DE, Verma A, et al. Intracardiac pulsed field ablation: proof of
340		feasibility in a chronic porcine model. Heart Rhythm 2019;16:754-764.
341	9.	Koruth JS, Kuroki K, Kawamura I, et al. Pulsed field ablation versus radiofrequency
342		ablation: Esophageal injury in a novel porcine model. Circ Arrhythm Electrophysiol
343		2020;13:e008303.

344	10. Samaniego EA, Derdeyn CP, Hayakawa M, Hasan D, Ortega-Gutierrez S. In vivo
345	evaluation of the new PHIL low viscosity in a swine rete mirabile model. Interv
346	Neuroradiol 2018;24:706–712.
347	11. Gabriel C, Peyman A, Grant EH. Electrical conductivity of tissues at frequencies below
348	1MHz. Phys Med Biol 2019;54:4863–4879.
349	12. Clarke JD, Piccini JP, Friedman DJ. The role of posterior wall isolation in catheter
350	ablation of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2021;32:2567–76.
351	13. Neven K, van Es R, van Driel V, et al. Acute and long-term effects of full-power
352	electroporation ablation directly on the porcine esophagus. Circ Arrhythm Electrophysiol
353	2017;10:e004672.

Structure	Electrogram amplitude, mV			Pacing threshold, mA		
	Pre-PFA	Post-PFA	<i>P</i> -value	Pre-PFA	Post-PFA	<i>P</i> -value
Atrium	1.52±1.19	0.17±0.16	<0.0001*	0.5±0.6	>15	< 0.001*
Atrial appendage	2.41±1.57	0.21±0.15	< 0.0001*	0.4±0.5	>15	<0.001*
Pulmonary vein	$0.92{\pm}0.79$	0.15±0.13	<0.0001*	0.7±0.4	>15	<0.001*
All structures	1.18±1.08	0.17±0.21	<0.0001*	0.6±0.7	>15	<0.001*

Table 1. Pre- versus post-PFA electrogram amplitude and pacing threshold.

356 *Significant *P*-value.

357 Figure Legends

358

359	Figure 1. CRC EP PFA catheters and system. Shown, are the designs of the CRC EP PFA
360	catheters and system. Each PFA catheter consists of an 8-French, 16-electrode, bidirectional,
361	spiral mapping/ablation catheter designed for single-shot ablation. The PFA catheters are
362	available in two diameter sizes (25-mm and 30-mm) with radiopaque tips and inserted through
363	an 8.5-Fr long introducer. The larger (30-mm) catheter has 4 distal mapping electrodes. The PFA
364	system delivers microsecond-wide, QRS-gated, bipolar, biphasic, pulsed electric fields
365	synchronized with the cardiac cycle which allows for ablation using individually-selected or all
366	electrodes.
367	
368	Figure 2. Electrical isolation following PFA confirmed by 3D mapping and intracardiac
369	electrograms. Shown, are post-PFA 3D voltage maps with corresponding surface (aV_F) and
370	intracardiac electrograms recorded using a high-density mapping catheter placed initially inside
371	the right superior (A) and subsequently in the right inferior (B) and left (C) PVs demonstrating
372	complete electrical isolation of all 3 PVs and a significant portion of the posterior wall.
373	CS=coronary sinus recording channels (proximal, mid and distal); HD=high-density (Advisor
374	
	HD Grid, Abbott) mapping catheter recording channels; LAA=left atrial appendage; LPV=left
375	HD Grid, Abbott) mapping catheter recording channels; LAA=left atrial appendage; LPV=left PV; RIPV=right inferior PV; RSPV=right superior PV.
375 376	HD Grid, Abbott) mapping catheter recording channels; LAA=left atrial appendage; LPV=left PV; RIPV=right inferior PV; RSPV=right superior PV.
375376377	 HD Grid, Abbott) mapping catheter recording channels; LAA=left atrial appendage; LPV=left PV; RIPV=right inferior PV; RSPV=right superior PV. Figure 3. Pre- and post-PFA voltage maps. 3D LA map created pre- (A) and post-PFA (B)

379 the 3D maps. C, Surface and intracardiac electrograms recorded during QRS-gated PFA using

- 380 the spiral ablation catheter. Also shown, are 3D LA maps created at baseline (**D**) and at 1 day (**E**)
- and 21 days (F) post-PFA. As seen, there is complete and durable isolation of all 3 PVs and also
- 382 a segment of the posterior wall. *LAA=left atrial appendage; RIPV=right inferior PV;*
- 383 RSPV=right superior PV.
- 384

385	Figure 4. Pre- and post-PFA maps of the left atrium and the PVs. 3D maps created pre- (A,
386	B), immediately post-PFA (D, E), and 3 months post-PFA (G, H), along with the corresponding
387	intracardiac electrograms (C, F, I) demonstrating electrical isolation of the right superior (RSPV)
388	and inferior (RSPV) and left PVs (LPV). J, Subgross histology illustrating complete,
389	circumferential and transmural fibrous replacement of the cardiac sleeve around the LPV. K,
390	Subgross histology of the RSPV demonstrating full-thickness, circumferential fibrous
391	replacement (blue staining, yellow outline) of the cardiac sleeve. Moreover, the treatment
392	extended to involve the myocardium from the posterior wall of the right atrium and a small
393	branch of the pulmonary artery (PA). L, Photomicrograph (hematoxylin and eosin)
394	demonstrating acute contraction band degeneration of cardiac myocytes consistent with PFA.
395	
396	Figure 5. Histology of lesions created using PFA. A, Sections of right superior pulmonary vein
397	(RSPV) illustrating a circumferential, transmural PFA lesion (arrow). A normal phrenic nerve
398	(arrow) following PFA depicted both on gross (B) and histologic examinations (C) after
399	deliberately performing PFA adjacent to this structure. As illustrated, no phrenic nerve injury has
400	occurred and the nerve is completely intact. D and E, Sections of RSPV and right inferior
401	pulmonary vein (RIPV) demonstrating circumferential ablation following PFA. F, Depicts a
402	higher magnification of panel D , demonstrating an area of transmural ablation (arrow) around

the circumference of the RSPV. G, Represents a higher magnification of panel D, demonstrating
transmural fibrous replacement of the muscular sleeve around the RSPV (arrow). H, Histologic
representation demonstrating fibrous replacement of the muscular sleeve (outlined) of the left
common pulmonary vein (LPV). I and J, illustrate higher magnifications of panel H, showing
transmural ablation (arrows) and replacement fibrosis of the muscular sleeve of the LPV with
normal surrounding epicardial fat and sparing of the nerve and artery.

409

410 Figure 6. Assessment for embolic events following PFA. Gross and histologic examination of 411 the porcine brain (A, B), the rete mirabile (C, D), and the kidneys (G, H) following PFA of the 412 atria, the atrial appendages, and the pulmonary veins using the CRC EP system showed no 413 evidence of embolization. Additionally, MRI was also performed to radiologically investigate for 414 embolic events. As shown, compared to baseline/pre-PFA (E), no gross or radiological 415 abnormalities suggestive of cerebral embolization were encountered in any of the animals on 416 MRI, 1 week post-PFA (F). DWI=diffusion-weighted imaging; GRE=gradient recalled echo T2-417 weighted; FLAIR=fluid attenuated inversion recovery; PD=proton density-weighted imaging; 418 *T1=T1-weighted.*

419

420 Figure 7. Histologic examination of the esophagus following PFA performed within the

421 adjacent IVC. A, Sections of porcine esophagus depicting normal tissue without evidence of

- 422 injury or lesions following PFA. **B**, Acute PFA-related changes (outlined) in the esophageal
- 423 muscular layer within 2 h of PFA with complete resolution during follow-up by 3 weeks.

424

425	Supplemental Figure 1. PFA from inside the IVC toward the adjacent deviated esophagus.
426	A, the esophagus was deviated toward the IVC using an esophageal retractor device (DV8;
427	Manual Surgical Sciences) as bipolar PFA (1.8–2.5 kV) was performed within the IVC through a
428	deflectable introducer at areas contacting the deviated esophagus. B, A 3D map depicts the
429	location of the spiral PFA catheter within the IVC at the time of ablation. CS=coronary sinus;
430	ESO=esophagus; SVC=superior vena cava.

431

432 Supplemental Figure 2. Assessment of chest contraction acceleration during following PFA. 433 Absolute chest contraction acceleration recorded during PFA in the left atrium, the PVs, and the 434 left atrial appendage (LAA). As seen, pulsed field applications delivered at anatomical locations 435 immediately adjacent to the left and right phrenic nerves (e.g., right superior PV or deep within 436 the LAA) was accompanied by prominent phrenic nerve capture, yielding acceleration levels of 5-9 m/s². Conversely, PFA using the same waveform parameters performed at anatomical sites 437 438 far enough from phrenic nerves (e.g., left PV or posterior wall) yielded no measurable chest contractions with an absolute mean acceleration of 0.05 m/s^2 indiscernible from background 439 440 noise.

CRC EP PFA Catheter System













Baseline

Posterior wall







E Post-PFA Day 1 Left PV

RSPV







QRS Gating During PFA



Post-PFA Day 21

RSPV

Posterior wall











